Skip to main content

Orion to host Capital Markets Day today, 22 May 2025, in Helsinki

Written by Customer Service on . Posted in Public Companies.

ORION CORPORATION
INVESTOR NEWS
22 MAY 2025 at 10.15 EEST
        

Orion to host Capital Markets Day today, 22 May 2025, in Helsinki

Orion hosts its Capital Markets Day for analysts, institutional investors, bankers, and media representatives in Helsinki today, 22 May 2025. At the event, members of the Orion Executive Management Board will discuss Orion’s growth strategy, financial objectives, and businesses. Orion will not publish new strategic or financial targets in connection with the event.

The presentation material is now published on Orion’s website https://www.orionpharma.com/cmd2025. The presentations include, among other things, the following information, which is of interest to investors, but is not considered to be material information about the company.

  • In the next 12 to 24 months, Orion aims to start clinical phase I trials with ODM-214, ODM-215 and ODM-216 which all are biologics (large molecule) and originate from Orion’s internal research.
  • Easyhaler® product portfolio has potential to exceed EUR 300 million in peak annual sales.

Orion has three biologics assets for immuno-oncology indications in late research (candidate drug) phase. The company aims to start clinical phase I trials with these assets in the next 12 to 24 months. Of the assets ODM-2014 and ODM-216 are bi-specific antibodies and ODM-215 is a CAR-T cell therapy.

The growth of Easyhaler® product portfolio for asthma and COPD is supported by the green transition. Dry-powder inhalers are becoming the preferred choice over metered-dose inhalers due to lower CO2 emissions. Also, the entire market is growing along with the growing number of patients. Orion is well positioned in this market and estimates that Easyhaler® product portfolio has potential to exceed EUR 300 million in peak annual sales.

Orion’s Capital Markets Day starts at 13:00 EEST and anyone can follow the event via a live webcast at https://orion.events.inderes.com/cmd-2025.

Orion Corporation

Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721

                                                 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com

Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion’s net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion’s A and B shares are listed on Nasdaq Helsinki.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.